TEGA Therapeutics, Inc. has been awarded a Phase I Small Business and Innovative Research (SBIR) grant ($461,701) from the National Institute of Neural Disorders and Stroke (NINDS) for the project “Development and Validation of Therapy for GM1 Gangliosidosis”. The award will fund preclinical research, administering enzyme replacement therapy directly to the brain for treating the neurological effects of GM1 gangliosidosis. With successful completion of the Phase I grant, TEGA will apply for a Phase II SBIR grant, which could potentially fund in the multimillion-dollar range to help advance the program to human clinical trials.
